Latest Regulatory News

Income Asset Management has resumed ASX trading after revealing a $1.5 million fraud involving a former employee, while assuring clients their assets remain secure under current custodianship.

Enegex Limited has voluntarily suspended trading on the ASX as it prepares to announce a significant acquisition and capital raising, heightening market anticipation.

Memphasys Limited has secured $0.84 million through a placement and announced a rights issue to raise up to $1.12 million, sharply cutting operating costs to accelerate commercialisation and manufacturing scale-up of its Felix™ bioseparation system.

Reece Limited has announced a $250 million off-market share buy-back priced between $11.00 and $13.00 per share, signaling confidence in its long-term strategy while maintaining financial flexibility.

Bank of Queensland Limited announces a fully franked quarterly distribution of AUD 1.2182 per Capital Note 3 security, reflecting a 4.89% annualised yield tied to the 3-month BBSW plus margin.

ADX Energy has secured a pivotal court ruling that allows it to resume drilling and testing at its Welchau-1 well in Austria, overcoming environmental objections and strengthening its exploration prospects.

Thunderbird Resources has executed a binding agreement to acquire 100% of the Springfield Gold Deposit in NSW, a drill-ready project with significant historical gold intercepts. The company also secured $2.2 million in funding to kickstart exploration.

Barton Gold Holdings has been added to the S&P Dow Jones ASX All Ordinaries Index, marking its rise among Australia's top 500 companies. The company is accelerating development of its South Australian gold projects, targeting significant production milestones by 2026.

Starpharma has entered a significant collaboration with Genentech to develop dendrimer-drug conjugates for oncology, securing an upfront payment and potential milestone earnings exceeding half a billion dollars.

Starpharma has entered a landmark collaboration with Genentech to develop innovative cancer therapies using its proprietary DEP® platform, securing $5.5 million upfront and potential milestones exceeding $560 million.

Resouro Strategic Metals has amended its private placement terms, aiming to raise CAD 3 million to fund engineering work for its Tiros Titanium-Rare Earths Project in Brazil.

PYC Therapeutics has restructured its Board and executive team to steer the company through pivotal clinical milestones expected by the end of 2027. The changes signal a strategic push toward late-stage development of its RNA-based drug candidates.